This review updates recent findings on the crosstalk between MYC and mTOR and targeted therapies that inhibit both MYC and mTOR along with other treatment modalities that hold potential to treat the Group 3 MYC-amplified medulloblastoma at the translational level. This evidence concerns the gene MYC and medulloblastoma.